Abstract
Introduction
Leukocyte adhesion deficiency (LAD) is a group of rare inherited disorders characterized by immune deficiency and peripheral neutrophilia. There are only seven reported cases of LAD type II worldwide, and no long-term follow-up data.
Case Report
We reviewed the medical file of a 20-year-old man with LAD II. Clinical characteristics included short stature, severe mental retardation, and autistic features. He had had no severe infections since infancy, and his current immunological status was stable. The last laboratory work-up revealed mild leukocytosis and neutrophilia. Genetic analysis of the Golgi GDP-fucose transporter (GFTP) sequence yielded a point mutation resulting in Y337C amino acid transition in the tenth transmembrane domain.
Conclusion
In conclusion, in LAD II, the main clinical countenance shifts from frequent infections due to immunodeficiency in the early years to the metabolic consequences of the defect in fucose metabolism, i.e., retarded growth and mental retardation, in the later years. A novel mutation in the GFTP loci associated with LAD II is described.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson DC, Smith CW. Leukocyte adhesion deficiencies. In: Scriver C, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001. p. 4829–56.
Bauer TR, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM, et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vector. Nat Med. 2008;14:93–7.
Yakubenia S, Wild MK. Leukocyte adhesion deficiency II advances and open questions. FEBS J. 2006;273:4390–8.
Marquardt T, Lühn K, Srikrishna G, Freeze HH, Harms E, Vestweber D. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 1999;94:3976–85.
Etzioni A, Tonetti M, Vestweber D, Marquardt T. Fucose supplementation in leukocyte adhesion deficiency type II. Blood. 2000;95:3641–3.
Alon R, Etioni A. LAD III, a novel group of leukocyte integrin activation deficiencies. Trends Immunol. 2003;24:561–6.
Mory A, Feigelson SW, Yarali N, Kilic SS, Bayhon GI, Gershoni-Baruch R. Kindlin-3: a new gene involved in the pathogenesis of LAD III. Blood. 2008;112:2591.
Svensson L, Howarth K, McDowall A, Patzak I, Evans R, Ussar S, et al. Leukocyte adhesion deficiency III is caused by mutations in Kindlin3 affecting integrin activation. Nat Med. 2009;15:306–12.
Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, Paulson JR, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med. 1992;327(25):1789–92.
Frydman M, Etzioni A, Eidlitz-Markus T, Avidor I, Varsano I, Shechter Y, et al. Rambam–Hasharon syndrome of psychomotor retardation, short stature, defective neutrophil motility, and Bombay phenotype. Am J Med Genet. 1992;44:297–302.
Etzioni A, Sturla L, Antonellis A, Green ED, Gershoni-Baruch R, Berninsone PM, et al. Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG)IIc founder effect and genotype/phenotype correlation. Am J Med Genet. 2002;110:131–5.
Marquardt T, Brune T, Lühn K, Zimmer KP, Korner C, Fahntz L, et al. Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J Pediatr. 1999;134:681–8.
Hidalgo A, Ma S, Peired AJ, Weiss LA, Cunningham-Rundles C, Frenette PS. Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood. 2003;101:1705–12.
Helmus Y, Denecke J, Yakubenia S, Robinson P, Luhn K, Watson DL, et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood. 2006;107:3959–66.
Etzioni A, Gershoni-Baruch R, Pollack S, Shehadeh N. Leukocyte adhesion deficiency type II: long-term follow-up. J Allergy Clin Immunol. 1998;102:323–4.
Frydman M, Vardimon D, Shalev E, Orlin JB. Prenatal diagnosis of Rambam–Hasharon syndrome. Prenat Diagn. 1996;16:266–9.
Wild MK, Lühn K, Marquardt T, Vestweber D. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs. 2002;172:161–73.
Lühn K, Marquardt T, Harm E, Vestweber D. Discontinuation of fucose therapy in LAD II causes rapid loss of selectin ligands and rise of leukocyte counts. Blood. 2001;97:330–2.
Sturla L, Puglielli L, Tonetti M, Berninsone P, Hirschberg CB, De Fiora A, et al. Impairment of the Golgi GDP-L-fucose transport and unresponsiveness to fucose replacement therapy in LAD II patients. Pediatr Res. 2001;49(4):537–42.
Aebi M, Helenius A, Schenk B, Barone R, Fiumara A, Berger EG, et al. Carbohydrate deficient glycoprotein syndrome becomes congenital disorder of glycosylation: an updated nomenclature for CDG. First International Workshop on CDGS. Glycoconj J. 1999;16:669–71.
Lübke T, Marquardt T, Etzioni A, Hartmann E, von Figura K, Körner C. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat Genet. 2001;28:73–6.
Lühn K, Wild MD, Gerardy-Schahn R, Vestweber D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. 2001;28:69–72.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gazit, Y., Mory, A., Etzioni, A. et al. Leukocyte Adhesion Deficiency Type II: Long-Term Follow-Up and Review of the Literature. J Clin Immunol 30, 308–313 (2010). https://doi.org/10.1007/s10875-009-9354-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-009-9354-0